Prilenia

Prilenia is a clinical-stage biotech company founded in 2018 with a focus on developing treatments for neurodegenerative and neurodevelopmental disorders. The company's lead asset, Pridopidine, is an oral drug candidate being evaluated for the treatment of Huntington’s disease in a global Phase 3 PROOF-HD trial and for ALS in the Phase 2/3 HEALEY platform trial. Led by Dr. Michael Hayden, MD, PhD, a highly experienced figure in the biotech industry, Prilenia has garnered attention for its potential in addressing multiple movement disorders and neurodegenerative diseases affecting both adults and children.

With headquarters in the United States and additional presence in Naarden, the Netherlands, Herzliya, Israel, and Boston, MA, the company secured a significant $43.00M Series B investment on 3 November 2021. Notable investors in this round included Forbion, Sands Capital Ventures, ALS Investment, Amplitude Ventures, Sectoral Asset Management, Talisman Capital Partners, and Morningside Venture Partners. Prilenia's dedication to addressing critical medical needs through innovative treatments positions it as a promising player in the biotechnology, health care, and pharmaceutical industries, making it an interesting prospect for potential future investment and partnership opportunities.